Rhabdomyosarcoma is a pediatric tumor of skeletal muscle that has used essentially the same chemotherapy drugs for treatment for decades. Despite attempts to improve the treatment, patients with disease recurrence still have relatively poor survival. Some rhabdomyosarcoma possess a ‘fusion’ between two genes that not only controls much of its biology, but also causes worse survival. In fact, in patients with metastatic or recurrent tumors that have the gene fusion, survival is <10%.
